ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AYTU vs JNJ // RSI-14 & 200D SMA MOMENTUM

Aytu BioPharma Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AYTU 1 — JNJ 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
rsi-technicals
62.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AYTU VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AYTU JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 69.00% 67.90% +1.10 AYTU /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield -10.06% 2.97% -13.03 JNJ /fcf-yield <GO>
Operating Margin -11.80% 34.70% -46.50 JNJ /operating-margins <GO>
Net Profit Margin -20.50% 28.50% -49.00 JNJ /net-margins <GO>
Revenue Growth (YoY) 1.80% 6.00% -4.20 JNJ /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 46.9 62.1 -15.20 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $21.5M $662.49B -$662.47B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AYTU REV JNJ REV AYTU GROSS % JNJ GROSS % AYTU FCF JNJ FCF
FY 2025 $66.4M $94.19B 69.0% 67.9% -$2.2M $19.70B
FY 2024 $65.2M $88.82B 75.3% 69.1% -$1.7M $19.84B
FY 2023 $107.4M $85.16B — — -$5.1M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AYTU // BETA —
JNJ // BETA 1.08